Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels

Part of paid clinical trials in Carlsbad, California.

Sponsor
Qualia Life Sciences
Study ID
NCT07132801
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • NAD
  • NAD+ Levels in the Blood

Eligibility Criteria

Sex
ALL
Age
35 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • Qualia NAD⁺ version 1 — DIETARY_SUPPLEMENT
    Qualia NAD+ version 1 manufactured by Qualia Life Sciences
  • Qualia NAD⁺ version 2 — DIETARY_SUPPLEMENT
    Qualia NAD+ version 2 manufactured by Qualia Life Sciences
  • Placebo — DIETARY_SUPPLEMENT
    Rice Flour

Study Details

This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.

Key Dates

Start date
Oct 13, 2025
Status verified
Jul 2025
Primary completion
Nov 30, 2025
Completion
Dec 15, 2025

Study Design

Enrollment
180 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Active Comparator: Qualia NAD⁺ version 1
  • Active Comparator: Qualia NAD⁺ version 2
  • Placebo Comparator: Placebo

Primary Outcome Measure

Between-group change in intracellular NAD⁺ levels [ Time Frame: 28 days ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Qualia Life SciencesCarlsbadCalifornia92011
Abhi Ardagh
[email protected]
855-281-2328

Find similar trials in Carlsbad, CA

By research site
Qualia Life Sciences· Carlsbad, CA

Related Studies